Correlation Engine 2.0
Clear Search sequence regions


  • Alpl (3)
  • Bglap (2)
  • cellular (2)
  • factor (4)
  • fibroblast (1)
  • Fmod (1)
  • ibuprofen (6)
  • ligament (1)
  • mice (1)
  • osteoblast (2)
  • parecoxib (5)
  • Runx2 (2)
  • tendon (3)
  • wound (1)
  • Sizes of these terms reflect their relevance to your search.

    The effects of cyclooxygenase (COX) inhibition following the reconstruction of the anterior cruciate ligament remain unclear. We examined the effects of selective COX-2 and nonselective COX inhibition on bone-tendon integration in an in vitro model. We measured the dose-dependent effects of ibuprofen and parecoxib on the viability of lipopolysaccharide- (LPS-) stimulated and unstimulated mouse MC3T3-E1 and 3T3 cells, the influence on gene expression at the osteoblast, interface, and fibroblast regions measured by quantitative PCR, and cellular outgrowth assessed on histological sections. Ibuprofen led to a dose-dependent suppression of MC3T3 cell viability, while parecoxib reduced the viability of 3T3 cultures. Exposure to ibuprofen significantly suppressed expression of Alpl (P < 0.01), Bglap (P < 0.001), and Runx2 (P < 0.01), and although parecoxib reduced expression of Alpl (P < 0.001), Fmod (P < 0.001), and Runx2 (P < 0.01), the expression of Bglap was increased (P < 0.01). Microscopic analysis showed a reduction in cellular outgrowth in LPS-stimulated cultures following exposure to ibuprofen and parecoxib. Nonselective COX inhibition and the specific inhibition of COX-2 led to region-specific reductions in markers of calcification and cell viability. We suggest further in vitro and in vivo studies examining the biologic and biomechanical effects of selective and nonselective COX inhibition.

    Citation

    Tim Schwarting, Sebastian Pretzsch, Florian Debus, Steffen Ruchholtz, Philipp Lechler. The Effect of Cyclooxygenase Inhibition on Tendon-Bone Healing in an In Vitro Coculture Model. Mediators of inflammation. 2015;2015:926369

    Expand section icon Mesh Tags

    Expand section icon Substances


    PMID: 26063979

    View Full Text